
自引率: 5.1%
被引量: 6426
通过率: 暂无数据
审稿周期: 2.69
版面费用: 暂无数据
国人发稿量: 19
投稿须知/期刊简介:
The European Journal of Gastroenterology and Hepatology has established a position as a leading forum in the field for the dissemination of original research. In addition to original articles, the journal features Reviews in Depth, each comprising a series of related reviews on an area of special interest, commentaries on some of the original research presented, and a News from Europe section highlighting forthcoming meetings and courses.
期刊描述简介:
The European Journal of Gastroenterology and Hepatology has established a position as a leading forum in the field for the dissemination of original research. In addition to original articles, the journal features Reviews in Depth, each comprising a series of related reviews on an area of special interest, commentaries on some of the original research presented, and a News from Europe section highlighting forthcoming meetings and courses.
-
Systematic review with meta-analysis of the effectiveness of subcutaneous biologics versus intravenous biologics in inflammatory bowel diseases.
被引量:- 发表:1970
-
Clinical and biochemical factors for bacteria in bile among patients with acute cholangitis.
被引量:- 发表:1970
-
Evaluation of online chat-based artificial intelligence responses about inflammatory bowel disease and diet: correspondence.
被引量:- 发表:1970
-
Reproductive and pregnancy control in Wilson disease patients in Spain.
Recommendations on pregnancy, lactation, and contraception in women with Wilson disease are briefly stated in international guidelines but are not entirely homogeneous. Data regarding the management of these special events among patients with Wilson disease in Spain are lacking. We used the Wilson Registry platform of the Spanish Association for the Study of the Liver to question patients on their reproductive and gestational lives. This was a multicentre ambispective study including adult women with Wilson disease in the Spanish Wilson Registry interviewed about their contraception, childbearing, pregnancy, and lactation experiences. Clinical and analytical data were extracted from the registry. The study included 92 women from 17 centres in Spain. Most (63%) reported having a previous pregnancy history. The rate of spontaneous miscarriages was 21.6%, mainly occurring in the first trimester and up to one third among undiagnosed patients. Most pregnant women received chelator therapy during pregnancy, but dose reduction was recommended in less than 10%. After delivery, artificial lactation predominated (60.3%) and its use was mainly based on physician's recommendations (68%). Up to 40% of the women included reported some concerns about their reproductive lives, mainly related to the potential drug toxicity to their children. Most of the patients considered the information given by specialists to be sufficient. Gestational management among women with Wilson disease in Spain was found to be highly heterogeneous and frequently different from what is described in international guidelines. Education on rare liver diseases should be a priority for scientific societies in order to homogenize patient follow-up and recommendations.
被引量:- 发表:1970
-
Subcutaneous versus intravenous infliximab therapy - a real-world study: toward higher drug concentrations.
Recently, a formula of subcutaneous infliximab (SC-IFX) has been approved for inflammatory bowel disease (IBD), demonstrating a better pharmacokinetic and immunogenic profiles, compared to intravenous infliximab (IV-IFX), with similar efficacy and safety. The aim of this study is to evaluate the clinical, biochemical, and pharmacological outcomes of IBD patients in clinical remission, who switched from IV-IFX to SC-IFX, with a follow-up period of 6 months. Retrospective cohort study, including IBD patients in clinical remission, previously medicated with IV-IFX, who switched to SC-IFX 120 mg every other week. Biochemical parameters were evaluated before the switch and 6 months after, namely infliximab serum concentrations, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and fecal calprotectin. Included 41 patients in clinical remission, 32 with Crohn's disease (78.0%) and 9 with ulcerative colitis (22.0%). All patients maintained clinical remission during the 6 months after the switch, with a treatment persistence rate of 100%, and no patients requiring corticosteroid therapy, switching back to IV-IFX, or IBD-related hospitalization. The mean infliximab serum concentrations were significantly higher after 6 months of SC-IFX (17.3 ± 6.6 vs. 9.1 ± 5.5 µg/ml, P < 0.001). However, there were no differences between values of ESR, CRP, and fecal calprotectin, before and after the switch ( P = 0.791, P = 0.246, and P = 0.639). Additionally, none of the patients developed antibodies to infliximab. Switching from IV-IFX to SC-IFX in IBD patients in clinical remission is effective and leads to higher infliximab serum concentrations, regardless of the combination with immunomodulatory therapy.
被引量:- 发表:1970